Johnson & Johnson: Depression trials

The registry lists 56 Depression studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 27 have results posted.

Early Phase 1 1Phase 1 9Phase 2 19Phase 3 17Phase 4 3No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT04985942Phase 3Results posted
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyTerminatedNCT04532749Phase 3Results posted
• A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderCompletedNCT04338321Phase 3Results posted
• Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderCompletedNCT04285515Phase 3Results posted
• A Study of JNJ-61393215 in the Treatment of DepressionCompletedNCT04080752Phase 2Results posted
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of DepressionCompletedNCT03559192Phase 2Results posted
• A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyCompletedNCT03321526Phase 2Results posted
• Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted GloballyCompletedNCT03249376Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyCompletedNCT03227224Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideCompletedNCT03185819Phase 2Results posted
• 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideCompletedNCT03097133Phase 3Results posted
• 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideCompletedNCT03039192Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant DepressionCompletedNCT02918318Phase 2Results posted
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionCompletedNCT02782104Phase 3Results posted
• Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar DepressionCompletedNCT02600507Phase 3Results posted
• An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious DistressCompletedNCT02498392Phase 2Results posted
• A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionCompletedNCT02497287Phase 3Results posted
• A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionCompletedNCT02493868Phase 3Results posted
• An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive DisorderCompletedNCT02473289Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionCompletedNCT02422186Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT02418585Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT02417064Phase 3Results posted
• A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideCompletedNCT02133001Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionCompletedNCT01998958Phase 2Results posted
• A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive DisorderTerminatedNCT01957410Phase 2Results posted
• A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety SymptomCompletedNCT01870843Phase 4Results posted
• A Study of Ketamine in Patients With Treatment-resistant DepressionCompletedNCT01627782Phase 2Results posted
• A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionWithdrawnNCT05268497Phase 1
• A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor AntidepressantTerminatedNCT05109195
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and PsychotherapyTerminatedNCT04951609Phase 1
• An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment AlternativesCompletedNCT04476446Phase 3
• A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive DisorderCompletedNCT04451187Phase 1
• A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive DisorderCompletedNCT03374475Phase 1
• Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal DepressionCompletedNCT03144752
• Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)CompletedNCT03014544
• A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive DisorderCompletedNCT02919579Phase 1
• A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive DisorderCompletedNCT02902601Phase 1
• Epidemiology of Treatment Resistant Depression in TaiwanCompletedNCT02691520
• Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)CompletedNCT02489305
• A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive DisorderCompletedNCT02476058Phase 1
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric ParticipantsCompletedNCT02087579Phase 1
• A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With AntidepressantsCompletedNCT02067299Phase 1
• An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety SymptomsCompletedNCT01814098Phase 4
• A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe DepressionCompletedNCT01814085Phase 4
• The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With DepressionTerminatedNCT01809340Phase 2
• A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant DepressionCompletedNCT01640080Phase 2
• A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety SymptomsCompletedNCT01582815Phase 2
• Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder PatientsCompletedNCT01533285Early Phase 1
• Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)CompletedNCT01402830
• Safety and Efficacy of EVT 101 in Treatment-Resistant DepressionTerminatedNCT01128452Phase 2
• A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive DisorderTerminatedNCT01114698Phase 2
• A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe DepressionCompletedNCT00566202Phase 2
• ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health RegistryCompletedNCT00264069
• Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard TherapyCompletedNCT00095134Phase 3
• A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive DisorderCompletedNCT00073203Phase 2
• A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant DepressionCompletedNCT00044681Phase 3